Asset
Dexamethasone
Ocular Therapeutix Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04050865 | phase3 | completed | 2019-08-05 | 2020-02-28 | Ocular Therapeutix, Inc. | A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis |
| NCT02062905 | phase2 | completed | 2014-03-01 | 2014-08-01 | Ocular Therapeutix, Inc. | OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis |
| NCT02089113 | phase3 | completed | 2014-04-01 | 2015-01-01 | Ocular Therapeutix, Inc. | OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery |
| NCT02468700 | phase2 | completed | 2015-01-01 | 2015-08-01 | Ocular Therapeutix, Inc. | OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye |
| NCT02445326 | phase3 | completed | 2015-04-01 | 2015-08-01 | Ocular Therapeutix, Inc. | OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 208742 | NDA | OCULAR THERAPEUTIX INC |
Marketed products (1)
- DEXTENZA